Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 16/20 | 0.38 |
| ▸ | CTRC | Q99895 | 2/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765764 | 0.96 | CMA1 (0.40) | CMA1CTRCCES2CTSG | |
| SCHEMBL30765604 | 0.89 | AVPR1B (0.34) | CMA1AVPR1B | |
| SCHEMBL30765987 | 0.87 | F2 (0.37) | CMA1CTRC | |
| SCHEMBL30765494 | 0.87 | F3 (0.34) | CMA1CTRCLMNA | |
| SCHEMBL30765579 | 0.86 | F3 (0.39) | CMA1CTRC | |
| SCHEMBL30765845 | 0.85 | TDP1 (0.36) | CMA1LMNAELANE | |
| SCHEMBL30765916 | 0.84 | CMA1 (0.41) | CMA1CTRCCTSGLMNAPOLB | |
| SCHEMBL31558452 | 0.83 | CMA1 (0.40) | CMA1CTRCCTSGLMNAELANE | |
| SCHEMBL30765601 | 0.81 | GAA (0.44) | CMA1CTRCCTSGLMNAPOLB | |
| SCHEMBL30765535 | 0.81 | F2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |